4//SEC Filing
Gujrathi Sheila 4
Accession 0001209191-23-021887
CIK 0001851194other
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 4:46 PM ET
Size
9.3 KB
Accession
0001209191-23-021887
Insider Transaction Report
Form 4
Gujrathi Sheila
Director
Transactions
- Exercise/Conversion
Common Stock
2023-03-30$6.03/sh+100,000$603,000→ 100,000 total - Sale
Common Stock
2023-03-30$33.73/sh−100,000$3,373,240→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-03-30−100,000→ 662,369 totalExercise: $6.03Exp: 2031-08-17→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]Represents the weighted average share price of an aggregate total of 100,000 shares sold in the price range of $33.50 to $33.97. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F2]Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 14, 2021.
Documents
Issuer
Ventyx Biosciences, Inc.
CIK 0001851194
Entity typeother
Related Parties
1- filerCIK 0001575202
Filing Metadata
- Form type
- 4
- Filed
- Mar 30, 8:00 PM ET
- Accepted
- Mar 31, 4:46 PM ET
- Size
- 9.3 KB